Dementia Care Practice.

Alzheimers Dement

University of Minnesota Duluth, Duluth, MN, USA.

Published: December 2024

This study was approved by the ethics review board at the University of Minnesota. In conclusion, the successful design and testing of an intelligent living space tailored for dementia care were conducted in a controlled lab environment with healthy participants. The primary aim was to assess the viability of integrating robots, wearable sensors, and spatial technology to support the well-being of individuals affected by dementia. Utilizing pressure sensors in chairs alongside the robot's emotion detection system effectively evaluated participants' moods, aligning with self-reported moods in 95∖% of cases. Additionally, door sensors accurately detected exiting behavior 100∖% of the time, while wall-mounted PIR sensors successfully identified wandering behavior. Wearable sensors, including EDA and blood pressure sensors, coupled with robot interactions, detected physiological changes during various activities, indicating the most significant impact during interactions with the robot. These findings suggest that an intelligent living space specifically designed for dementia care can effectively preserve the quality of life for affected individuals, particularly through robot interactions, showcasing promising effectiveness.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.085672DOI Listing

Publication Analysis

Top Keywords

dementia care
12
intelligent living
8
living space
8
wearable sensors
8
pressure sensors
8
robot interactions
8
sensors
6
dementia
4
care practice
4
practice study
4

Similar Publications

Alzheimer's disease (AD) is the most frequent cause of dementia. Since there are complex pathophysiological mechanisms behind AD, and there is no effective treatment strategy, it is necessary to introduce novel multi-targeting agents with fewer side effects and higher efficacy. Polydatin (PD) is a naturally occurring resveratrol glucoside employing multiple mechanisms toward neuroprotection.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Background: The MarkVCID consortium was established to address the paucity of biomarkers for vascular contributions to cognitive impairment and dementia (VCID), a leading cause of dementia. Plasma neurofilament light (NfL), a neuroaxonal injury marker elevated in several neurological and neurodegenerative diseases, was selected as one of the first biomarkers to be examined. We performed comprehensive instrumental and clinical validation of the Quanterix Simoa NfL assay using the first MarkVCID cohort.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

University of Oxford, Oxford, United Kingdom.

Background: Alzheimer's disease (AD) impacts over 50 million individuals and imposes a substantial burden on patients, caregivers, and society at large. Recent research suggests that AD is a continuum comprising preclinical, prodromal, and dementia stages, with underlying pathology manifesting well before symptoms appear. Early and accurate diagnosis is therefore crucial for optimal clinical outcomes; yet current diagnostic methods, such as neuroimaging and cerebrospinal fluid lumbar puncture, are expensive and invasive.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Eisai Inc., Nutley, NJ, USA.

Background: Recent advances in diagnostics have made it possible to identify early signs of the pathophysiological changes underlying Alzheimer's Disease (AD) via blood tests. However, the use of blood-based biomarkers (BBBMs) for the early detection of AD may be limited in primary care settings despite its potential for wide access and early detection of AD (PMID: 37295421) Therefore, there is a need to understand the barriers and facilitators of BBBM testing for AD in primary care.

Method: We employed a combination of qualitative research, advisory board, and quantitative survey to engage with clinical/scientific advisors and community-based physicians in primary care.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA.

Background: APOE genotype is the most important genetic risk factor for Alzheimer's disease (AD), but whether it affects the proteins associated with AD risk is unclear. Circulating proteins may reveal biology underlying pathologic processes.

Methods: We evaluated log2 standardized levels of 4979 proteins quantified using modified aptamer technology [SomaScan] in plasma from 2725 participants in the Cardiovascular Health Study who were free of dementia and stroke.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!